Empagliflozin: Validation of Stability-Indicating LC Method and in silico Toxicity Studies

Author:

da Silva Andressa Tassinari1,Brabo Gabriela Rossi1,Porto Douglas dos Santos1ORCID,da Silva Jonco Jaizor12,Bajerski Lisiane1,Paula Fávero Reisdorfer12,Paim Clésio Soldateli12

Affiliation:

1. Universidade Federal do Pampa (UNIPAMPA–Campus Uruguaiana-RS) Laboratório de Pesquisa em Desenvolvimento e Controle de Qualidade; Curso de Farmácia, , BR 472–Km 585, CEP 97500-970, Uruguaiana (RS) , Brasil

2. Universidade Federal do Pampa (UNIPAMPA–Campus Uruguaiana-RS) Programa de Pós-Graduação em Ciências Farmacêuticas, Curso de Farmácia, , BR 472–Km 585, CEP 97500-970, Uruguaiana (RS) , Brasil

Abstract

Abstract A new stability-indicating liquid chromatography method was developed for the quantification of empagliflozin and two synthetic impurities. The chromatographic conditions included Spherisorb® RP-18 column (150 × 4.6 mm, 5 μm) with a PDA detector, using acetonitrile and formic acid (pH 4.0) as mobile phase in gradient elution and flow-rate of 1.2 mL·min−1. The gradient increasing from 51 to 100% acetonitrile until 11.00 min, followed by decreasing the solvent from 100% to the initial ratio from 11.01 to 15.00 min. The method was validated according to International Council of Harmonization guidelines. The LOD and LOQ values for impurities A and B were 35 and 15 ng·mL−1, respectively, (for LOD) and 115 and 35 ng.mL−1, respectively (for LOQ). The method was linear in the range of 80–140, 115–1150 and 35–350 ng·mL−1 for EMPA, impurities A and B, respectively, and the correlation coefficient were > 0.999 in all situations, indicating the method good linearity. The developed method showed a good recovery for empagliflozin and added impurities. The method has proven to be precise, demonstrated values less than 2.0% to empagliflozin and 5.0% to synthetic impurities, robust and selective with no interference from other products in the determination of analytes. The in silico toxicity prediction suggested that the impurities do not present any toxicity risk for the parameters evaluated.

Funder

Federal University of Pampa

CNPq

Publisher

Oxford University Press (OUP)

Subject

General Medicine,Analytical Chemistry

Reference34 articles.

1. Depression and diabetes;Sartorius;Dialogues in Clinical Neuroscience,2018

2. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment;Macha;Diabetes, Obesity and Metabolism,2014

3. A new validated RP-HPLC method for the determination of metformin HCl and Empagliflozin in its bulk and pharmaceutical dosage forms;Godasu;International Journal of Pharmaceutical Sciences and Research,2017

4. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;The New England Journal of Medicine,2015

5. A current review on analytical tools for determination of new oral antidiabetic drugs, Empagliflozin, Linagliptin and Biguanides in bulk materials, pharmaceuticals & biological samples;Baokar;Journal of Pharmaceutical Research International,2020

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3